Display options
Cite
Matthaios D, Tolia M, Mauri D, et al. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines. 2021;9(12)doi: 10.3390/biomedicines9121949.
Matthaios, D., Tolia, M., Mauri, D., Kamposioras, K., & Karamouzis, M. (2021). YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines, 9(12), . https://doi.org/10.3390/biomedicines9121949
Matthaios, Dimitrios, et al. "YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango." Biomedicines vol. 9,12 (2021). doi: https://doi.org/10.3390/biomedicines9121949
Matthaios D, Tolia M, Mauri D, Kamposioras K, Karamouzis M. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Biomedicines. 2021 Dec 20;9(12). doi: 10.3390/biomedicines9121949. PMID: 34944765.
Copy Download .nbib Format: NLM
Share it on

Biomedicines. 2021 Dec 20;9(12). doi: 10.3390/biomedicines9121949.

YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango.

Biomedicines

Dimitrios Matthaios, Maria Tolia, Davide Mauri, Konstantinos Kamposioras, Michalis Karamouzis

Affiliations

  1. Department of Medical Oncology, Rhodes General Hospital, 85100 Rhodes, Greece.
  2. Department of Radiotherapy, School of Medicine, University of Crete, 71500 Heraklion, Greece.
  3. Department of Medical Oncology, University of ?oannina, 45110 ?oannina, Greece.
  4. Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK.
  5. Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

PMID: 34944765 DOI: 10.3390/biomedicines9121949

Abstract

Hippo pathway with its main molecule YAP is a crucial pathway for development, tissue homeostasis, wound healing, tissue regeneration, and cancer. In this review, we discuss the multiple effects of the YAP/Hippo pathway in the immune system and cancer. We analyzed a series of effects: extracellular vesicles enhanced immunity through inhibition of LATS1/2, ways of modulation of the tumor microenvironment, YAP- and TAZ-mediated upregulation of PDL1, high expression of YAP and PDL1 in EGFR-TKI-resistant cells, enhanced YAP activity in inflammation, and the effect of the Hippo pathway on T cells, B cells, Tregs, macrophages, and myeloid-derived suppressor cells (MDSCs). These pleiotropic effects render the YAP and Hippo pathway a key pathway for exploitation in the future, in order to enhance our immunotherapy treatment strategies in oncology.

Keywords: Hippo pathway; LATS1/2; TAZ; YAP; cancer; immunity; immunotherapy

References

  1. Cell. 2016 Dec 1;167(6):1525-1539.e17 - PubMed
  2. Cancer Cell. 2019 Jun 10;35(6):868-884.e6 - PubMed
  3. Cancers (Basel). 2018 Mar 20;10(3): - PubMed
  4. Trends Cell Biol. 2017 Mar;27(3):172-188 - PubMed
  5. Nat Cell Biol. 2008 Dec;10(12):1470-6 - PubMed
  6. J Biol Chem. 2018 Dec 14;293(50):19290-19302 - PubMed
  7. FEBS Open Bio. 2015 Jun 22;5:542-9 - PubMed
  8. Tumour Biol. 2015 Jul;36(7):4889-904 - PubMed
  9. Cell. 2006 Feb 10;124(3):615-29 - PubMed
  10. Oncol Rep. 2018 Oct;40(4):2171-2182 - PubMed
  11. Nat Cell Biol. 2003 Oct;5(10):921-7 - PubMed
  12. Eur J Immunol. 2010 Dec;40(12):3317-20 - PubMed
  13. FEBS Lett. 2016 Jan;590(1):68-75 - PubMed
  14. Nat Cell Biol. 2015 Sep;17(9):1218-27 - PubMed
  15. J Med Chem. 2018 Jun 28;61(12):5057-5072 - PubMed
  16. Sci Rep. 2018 Jan 10;8(1):271 - PubMed
  17. Oncotarget. 2017 Dec 8;9(4):4637-4646 - PubMed
  18. Cancer Biol Ther. 2013 May;14(5):390-8 - PubMed
  19. Cell Host Microbe. 2018 Sep 12;24(3):429-438.e6 - PubMed
  20. Cancer Res. 2018 May 1;78(9):2305-2317 - PubMed
  21. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3794-9 - PubMed
  22. Genes Dev. 2017 Feb 1;31(3):247-259 - PubMed
  23. Oncogene. 2014 Mar 13;33(11):1468-74 - PubMed
  24. Cancer Res. 2018 Mar 15;78(6):1457-1470 - PubMed
  25. Cancers (Basel). 2018 Mar 28;10(4): - PubMed
  26. Cell Rep. 2018 Oct 16;25(3):702-714.e6 - PubMed
  27. Cancer Discov. 2016 Jan;6(1):80-95 - PubMed
  28. Biochem Biophys Res Commun. 2017 Sep 16;491(2):493-499 - PubMed
  29. Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1643-1648 - PubMed
  30. Cancer Discov. 2018 Aug;8(8):1026-1043 - PubMed
  31. Cancer Cell Int. 2020 Oct 12;20:495 - PubMed
  32. Cancer Res. 1958 Oct;18(9):992-1003 - PubMed
  33. Genes Dev. 2017 Feb 1;31(3):223-225 - PubMed
  34. Mol Biol Cell. 2015 Nov 5;26(22):3946-53 - PubMed
  35. Structure. 2012 Jul 3;20(7):1135-40 - PubMed
  36. Sci Rep. 2016 Aug 01;6:30483 - PubMed
  37. Immunology. 2018 Oct;155(2):263-272 - PubMed
  38. Eur J Immunol. 2015 Apr;45(4):999-1009 - PubMed
  39. Nano Today. 2015 Jun 1;10(3):397-409 - PubMed
  40. Mol Cell. 2003 Jan;11(1):11-23 - PubMed
  41. Mol Cell. 2015 Oct 15;60(2):328-37 - PubMed
  42. Cancer Res. 2010 Dec 1;70(23):9621-30 - PubMed
  43. J Hematol Oncol. 2017 Feb 28;10(1):60 - PubMed
  44. Biomaterials. 2018 Apr;161:164-178 - PubMed
  45. Nat Immunol. 2017 Jul;18(7):800-812 - PubMed
  46. J Biol Chem. 2012 Jun 22;287(26):22089-98 - PubMed
  47. Biochem Biophys Res Commun. 2016 May 20;474(1):154-160 - PubMed
  48. Cancer Lett. 2017 Aug 28;402:61-70 - PubMed
  49. Cancer Cell. 2014 Feb 10;25(2):166-80 - PubMed
  50. Oncotarget. 2018 Feb 6;9(18):14175-14192 - PubMed
  51. Immunity. 2012 Mar 23;36(3):374-87 - PubMed
  52. PLoS Genet. 2015 Aug 21;11(8):e1005465 - PubMed
  53. J Am Chem Soc. 2019 Mar 13;141(10):4257-4263 - PubMed
  54. Oncogene. 2017 Jan 26;36(4):534-545 - PubMed
  55. Theranostics. 2020 Feb 18;10(8):3622-3635 - PubMed
  56. Cell Physiol Biochem. 2017;41(3):1189-1198 - PubMed
  57. J Transl Med. 2015 Feb 01;13:47 - PubMed
  58. Nat Rev Cancer. 2013 Oct;13(10):739-52 - PubMed
  59. Cancer Res. 2007 Jan 15;67(2):585-92 - PubMed
  60. Nat Cell Biol. 2014 Apr;16(4):357-66 - PubMed
  61. Front Immunol. 2020 Aug 04;11:1473 - PubMed
  62. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9 - PubMed
  63. J Cell Mol Med. 2018 Jun;22(6):3139-3148 - PubMed
  64. Oncoimmunology. 2016 Mar 28;5(6):e1160187 - PubMed
  65. Blood Adv. 2016 Dec 14;1(3):219-230 - PubMed
  66. J Immunol. 2009 Sep 15;183(6):3720-30 - PubMed
  67. Cell Rep. 2015 Jul 14;12(2):244-57 - PubMed
  68. Nat Med. 2014 Jun;20(6):599-606 - PubMed
  69. J Biol Chem. 2013 Apr 12;288(15):10849-59 - PubMed
  70. Front Immunol. 2014 Jun 17;5:276 - PubMed
  71. Blood Adv. 2018 Sep 25;2(18):2282-2295 - PubMed
  72. J Clin Invest. 2012 Nov;122(11):4094-104 - PubMed
  73. Nat Cell Biol. 2008 May;10(5):619-24 - PubMed
  74. J Exp Clin Cancer Res. 2019 Feb 8;38(1):62 - PubMed
  75. Genes Dev. 2012 Jun 15;26(12):1300-5 - PubMed
  76. Oncogene. 2017 Mar 2;36(9):1232-1244 - PubMed
  77. J Transl Med. 2010 Feb 08;8:13 - PubMed
  78. Front Immunol. 2020 May 06;11:733 - PubMed
  79. PLoS One. 2012;7(10):e47045 - PubMed
  80. Genes Dev. 2017 Jun 1;31(11):1109-1121 - PubMed
  81. Nat Rev Cancer. 2004 Jan;4(1):71-8 - PubMed
  82. Mol Cell. 2008 Feb 15;29(3):350-61 - PubMed
  83. Gut. 2018 Sep;67(9):1692-1703 - PubMed
  84. Cancer Immunol Res. 2018 Mar;6(3):255-266 - PubMed
  85. Immune Netw. 2020 Oct 19;20(5):e36 - PubMed

Publication Types